182 results about "Keloid" patented technology

Devices, kits and methods described herein may be for treatment to skin, including but not limited to wound healing, the treatment, amelioration, and / or prevention of scars or keloids. A book-like packaging, applicator and / or tensioning device may be used to apply a dressing to a subject. The packaging, applicator and / or tensioning device may apply and / or maintain a strain in an elastic dressing.

A scar dressing of thin polymeric film having a thickness no greater than about 10 mils (0.254 mm) is disclosed. The film is preferably coated on one side with a hypoallergenic pressure-sensitive adhesive, and the dressing as a whole has a permeability profile for moisture vapor and oxygen that renders the dressing particularly suitable for treating scar tissue, particularly where the scarring has become, or may become, hypertropic or keloidal.

The present invention relates generally to the field of prophylaxis and therapy for inflammatory and / or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and / or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and / or treat inflammatory and / or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and / or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.

The invention is generally a skin treatment for managing skin conditions ranging from scars, including keloids, to burns and wrinkles. The skin treatment may comprise of several components including a cleansing solution, a silicone elastomer, and a mineral powder that may be utilized to treat and camouflage the affected skin. In one embodiment, a cleansing component is used to prime a skin area, cleansing and treating the area so that a silicone component can heal the skin.

The present invention provides a stabilized foam having a crosslinked closed cell polyolefin foam having a top and a bottom surface; a stabilizing layer disposed onto at least one of the top and the bottom surfaces of the crosslinked closed cell polyolefin foam; and an adhesive layer disposed onto at least one of the top or the bottom surfaces. Also provided is a method of preparing the stabilized foam, a method of treating a wound, scrape, abrasion or skin puncture, a method of maintaining cleanliness of an operation incision site, suture site, catheter insertion site, or an intentional skin breach site, a method of monitoring electrical impulses during EKG or delivering electrical impulses in a TENS or biofeedback therapy, and a method of softening the collagen deposits on a scar and reducing the raised or keloid portion of the scar over time.

Devices, kits and methods described herein may be for wound healing, including the treatment, amelioration, or prevention of scars and / or keloids by applying and / or maintaining a pre-determined strain in an elastic skin treatment device that is then affixed to the skin surface using skin adhesives to transfer a generally planar force from the bandage to the skin surface. Applicators are used to apply and / or maintain the strains, and some of the applicators are further configured to provide at least some mechanical advantage to the user when exerting loads onto the skin treatment device.

The present invention discloses compositions and methods for the prevention and treatment of skin and hair diseases, such as, for example, alopecia, psoriasis, and keloids. The present invention also relates to compositions and methods for altering skin coloration. The present invention also relates to methods for enhancing the effect of a neurotoxin.

Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and / or a non-steroidal anti-inflammatory drug (NSAID) to a subject.

Disclosed herein is a method for suppressing the growth of cancer cells in a mammal in need of such treatment comprising administering to said mammal a cancer cell suppressing amount of a diphenylmethylpiperazine represented by the following general formula [1]:wherein R represents:or a pharmaceutically acceptable salt thereof.Compared with conventional anticancer agents, these agents are less toxic and exert an excellent carcinostatic effect on various solid cancers. Moreover, these anticancer agents inhibit the proliferation of fibroblasts, which makes them efficacious against pulmonary fibrosis and proliferative keloid lesions.

This invention is in the field of medicinal chemistry and relates to novel compounds, and pharmaceutical compositions and methods of use thereof for the treatment and / or prevention of fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring / wound healing abnormalities, post operative adhesions, and reactive fibrosis. The invention also relates to methods of using the compounds and pharmaceutical compositions of this invention to treat fibrotic conditions.

The present invention provides compositions of saratin and methods of use thereof. One aspect of the invention is a method of prevention or mitigation of the development of adhesions, keloids and scars. The adhesions, keloids and scars can be due to surgery, such as plastic surgery or orthopedic surgery, or can be pre-existing scars. Another aspect of the invention is a method for treatment of flexor tendon injuries.

The invention discloses a scar repair material which is prepared by the following method: dissolving 0.5-5 parts by weight of water-soluble chitosan or chitosan the deacetylation degree of which is 75-97% into 10-100 parts by weight of water or an acetic acid aqueous solution the mass concentration of which is 1-5% while stirring; adding 1-3 parts by weight of polyoxyethylene Sorbitan lauric acid monoester which has emulsifying action and 5-10 parts by weight of humectant glycerol to obtain a transparent gelatinous solution; adding 20-90 parts by weight of polydimethylsiloxane into the gelatinous solution under homogeneity; and evenly mixing to obtain the scar repair material. The scar repair material disclosed in the invention can actively and passively moisturize skin, has the efficacy on actively resisting and inhibiting bacteria, has the action on quickening the healing of skin wound surface, has better repair and protection actions on tiny flaws and infection on the scar surface as being used on the scar surface, and can inhibit the secretion of collagen type I in cheloid skin so as to lower the ratio of collagen type I / collagen type III.

The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.

A method for treating a scar on a skin surface of a subject is provided. A subject is identified as having a skin surface with scar tissue. In response to identifying the subject as having the scar tissue, a housing comprising at least one acoustic transducer is placed on the skin surface with the scar tissue and the acoustic transducer is activated to apply high intensity focused ultrasound energy to a portion of the scar tissue. Other embodiments are also described.

A pharmaceutical preparation for preventing and / or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist. More specifically, there is provided a pharmaceutical preparation for preventing and / or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist such as an anti-erythropoietin antibody, an erythropoietin receptor protein, etc. This pharmaceutical preparation has excellent prophylactic and / or therapeutic effects on collagenous hyperproliferation such as hypertrophic scars, keloid, etc., or chronic arthritic diseases such as rheumatoid arthritis, etc.

Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and / or a non-steroidal anti-inflammatory drug (NSAID) to a subject.

The present invention relates to an agent for reducing scar formation, which inhibits the scar formation by injecting sodium bicarbonate to the dermis tissue of the wound with a syringe to directly control pH of the wound site, namely, by alkalinizing the wound to inactivate TGF-beta. According to the present invention, the agent for reducing scar formation by controlling the wound healing process can be clinically and immediately applied to the treatment of tylosis scar and keloid, etc., and is effective to the treatment of intractable fibrosis diseases. Also, the invention can be widely applied in many ways as an easy tool which can control the action of TGF-beta in a living organism.

This invention relates to pharmaceutical compositions comprising a sulfonated biological precursor of thymidine, such as a precursor of 4-thiothymidine (4-TT), and their use in the photodynamic treatment of skin hyperplasias, including cancer, psoriasis, actinic keratosis and keloids, by topical or systemic administration.

The present invention provides compositions of saratin and methods of use thereof. One aspect of the invention is a method of prevention or mitigation of the development of adhesions, keloids and scars. The adhesions, keloids and scars can be due to surgery, such as plastic surgery or orthopedic surgery, or can be pre-existing scars. Another aspect of the invention is a method for treatment of flexor tendon injuries.

A composition for repressing transformation growth factor β contains theanine as an active substance. The composition is useful for preventing or treating chronic glomerulonephritis, renal interstitial fibrosis, hepatic fibrosis, hepatic cirrhosis, idiopathic interstitial pneumonia, keloid, hidebound disease, arterial sclerosis, myocardial infarction, cardiac fibrosis, restenosis, acute megakaryoblastic leukemia, adult T-cell leukemia, chronic fatigue syndrome or ordinary fatigue.

A method for the treatment of scars and keloids is disclosed. The treatment involves an effective dose of the demethylating agents, 5-azacytidine and 2-deoxy-5-azacytidine. The method also discloses treating skin cancer with a combination therapy comprised of UV radiation and topical application or administration of the above mentioned demethylating agents.

The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.

Devices, kits and methods described herein may be for treatment to skin, including but not limited to wound healing, the treatment, amelioration, and / or prevention of scars or keloids. A book-like packaging, applicator and / or tensioning device may be used to apply a dressing to a subject. The packaging, applicator and / or tensioning device may apply and / or maintain a strain in an elastic dressing.

An effective treatment for skin disorders characterized by abnormal skin cell behavior, including a pharmaceutically effective amount of Halofuginone. Skin disorders which can be treated include keloids, hypertrophic scars, psoriasis, acne, seborrhea and alopecia. Halofuginone can reduce or eliminate clinical symptoms of these disorders, as well as substantially prevent the formation of keloids and hypertrophic scars.

Devices, kits, systems and methods are described herein for treatment to skin, including but not limited to wound healing, the treatment, amelioration, and / or prevention of scars or keloids. Certain devices kits, systems and methods are used to select treatment parameters, devices or methods for treating skin in a location, zone, or region of skin having particular mechanical or other properties.

The invention relates to the field of medical / cosmetic apparatuses, and in particular relates to scar-repairing silica gel containing human-like collagen, wherein the rapid transdermal absorption of the human-like collagen can be promoted. The scar-repairing silica gel can be used for repairing hyperplastic scars or keloids caused by burns, scalds, trauma, operations and the like in the medical / cosmetic field. The scar-repairing silica gel contains the human-like collagen, silica, cyclopentasiloxane, dimethiconol, water and polydimethylsiloxane.

A pharmaceutical preparation for preventing and / or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist. More specifically, there is provided a pharmaceutical preparation for preventing and / or treating hypertrophic scars, keloid or chronic arthritic diseases comprising as an effective component an erythropoietin antagonist such as an anti-erythropoietin antibody, an erythropoietin receptor protein, etc. This pharmaceutical preparation has excellent prophylactic and / or therapeutic effects on collagenous hyperproliferation such as hypertrophic scars, keloid, etc., or chronic arthritic diseases such as rheumatoid arthritis, etc.

The invention relates to a microneedle patch for treating keloid as well as a kit and application. The microneedle patch does not contain medicine, and comprises a substrate and a microneedle array arranged on the substrate, wherein the microneedle array comprises a plurality of microneedles; the gap between each microneedle is not smaller than 200 microns; each microneedle length is 300 to 1000 microns; the microneedle material is nonmetal which cannot generate swelling on the skin, cannot be softened and cannot cause skin itch or irritability. The microneedle patch does not depend on medicine or other bioactive substances for inhibiting the growth of fibrotic lesion; the treatment mode has the cost advantage and has a small side effect.

The present invention is related to the use of benzazole derivatives of formula (I) for the treatment and / or prevention of scleroderma and its therapeutic implications selected in the group consisting of systemic sclerosis, scleroderma-like disoders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, Dupuytren's contracture, keloid and other scarring / wound healing abnormalities, postoperative adhesions and reactive fibrosis, as well as chronic heart failure, in particular after myocardial infarction.